Receptos — 2014 Joint ACTRIMS-ECTRIMS Meeting
17 slides from Receptos's conference presentation, Sep 15, 2014
Slide 1: Phase 2 Results of the RADIANCE Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Exhibit 99.1 2014 Joint ACTRIMS-ECTRIMS Meeting Boston, Massachusetts Phase 2 Results of the RADIANCE Trial: A Randomized, Double-Blind, Placebo-Controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Amit Bar-Or, MD September 13, 2014 1 J Cohen , DL Arnold 2,3, G Comi 4, A Bar-Or 5, S Gujr
Slide 2: Conflict of Interest Statements
Conflict of Interest Statements Amit Bar-Or: financialsupportfrom BiogenIdec,DioGenix,Genentech, GlaxoSmithKline, Guthy-Jackson Charitable Foundation, Medimmune, Merck Serono, Novartis, Ono Pharmaceuticals, Receptos, Roche, Sanofi- Aventis, and Teva Neuroscience JCohen: financialsupportfrom EMDSeron
Slide 3: Introduction
Introduction Immunomodulation through the sphingosine 1-phosphate (S1P) receptor family is a validated therapeutic approach for the treatment of relapsing multiple sclerosis (RMS) RPC1063 is a novel, oral S1P1,5R modulator in clinical development for RMS by Receptos, Inc., which has only been previo
Slide 4: RADIANCE Patient Population: Key Inclusion Criteria
RADIANCE Patient Population: Key Inclusion Criteria MS, as diagnosed by the revised McDonald criteria (2010) Exhibiting a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS Ages 18-55 years, inclusive EDSS at Baseline between 0 and 5.0 points, inclusive
Slide 5: RADIANCE Phase 2 Trial Design
RADIANCE Phase 2 Trial Design 24-Week Placebo-Controlled Blinded Safety- 7-day 30-day Titration Treatment Period Extension Screening Period Period 1 mg RPC1063 1 mg RPC1063 Randomization 0.5 mg RPC1063 0.5 mg RPC1063 1 mg RPC1063 Placebo 0.5 mg RPC1063 Week -4 0 1 4 8 12 16 20 24 MRI Baseline Safety
Slide 6: Patient Disposition
Patient Disposition Randomized (N=258) Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) Discontinued 3 (3.4%) Discontinued 2 (2.3%) Discontinued 1 (1.2%) Adverse event 0 Adverse event 0 Adverse event 0 Lost to follow-up 1 (1.1%) Lost to follow-up 0 Lost to follow-up 0 Protocol violation 0 Pr
Slide 7: Patient Demographics and RMS Disease History
Patient Demographics and RMS Disease History Placebo RPC1063 0.5 mg RPC1063 1 mg Demographics (N=88) (N=87) (N=83) Female – n (%) 62 (70.5) 60 (69.0) 59 (71.1) Age (yrs) 39.0 (8.7) 38.1 (9.2) 38.4 (9.8) RMS Disease History, mean (SD) Years since MS diagnosis 4.6 (5.1) 2.8 (5.0) 3.6 (4.4) EDSS Score
Slide 8: Primary Endpoint: Cumulative Number of Total GdE Lesions From Weeks 12 to 24
Primary Endpoint: Cumulative Number of Total GdE Lesions From Weeks 12 to 24 14 12 11.1 10 8 86% decrease 86% decrease 6 p < 0.0001 p < 0.0001 4 2 1.5 1.5 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 8 ACTRIMS-ECTRIMS 2014
Slide 9: Secondary Endpoint (1): Mean Number of GdE Lesions at Week 24
Secondary Endpoint (1): Mean Number of GdE Lesions at Week 24 3.5 3.2 3 2.5 2 91% decrease 94% decrease 1.5 p < 0.0001 p < 0.0001 1 0.5 0.3 0.2 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 9 ACTRIMS-ECTRIMS 2014
Slide 10: Secondary Endpoint (2): Cumulative Number of New or Enlarging T2 Lesions
Secondary Endpoint (2): Cumulative Number of New or Enlarging T2 Lesions From Weeks 12 to 24 12 10 9.0 8 6 84% decrease 91% decrease p < 0.0001 p < 0.0001 4 2 1.4 0.8 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 10 ACTRIMS-ECTRIMS 2014
Slide 11: Secondary Endpoint (3): Annualized Relapse Rate
Secondary Endpoint (3): Annualized Relapse Rate 0.6 0.5 0.5 31% decrease p = 0.271 53% decrease 0.4 p = 0.053 0.35 0.3 0.24 0.2 0.1 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 11 ACTRIMS-ECTRIMS 2014
Slide 12: Pharmacodynamic Effect of RPC1063
Pharmacodynamic Effect of RPC1063: Mean ± SE Percent Change in Absolute Lymphocyte Counts 0 -20 -40 ~ 50% -60 ~ 60% 0 4 12 24 Study Week Program: E:\SASData\rpc1063\201a\csr\prog\g_lymph.sas 08JUN2014 13 September 2014 12 ACTRIMS-ECTRIMS 2014
Slide 13: Safety: Treatment Emergent Adverse Events
SAFETY: Treatment Emergent Adverse Events, n (%) (All 24-week Double blind phase) Placebo RPC1063 0.5 mg RPC1063 1 mg (N=88) (N=87) (N=83) Number of subjects experiencing 1 TEAE 52 (59.1) 56 (64.4) 47 (56.6) 1 moderate or severe TEAE 23 (26.1) 24 (27.6) 13 (15.7) 1 severe TEAE 1 (1.1) 2 (2.3) 1 (1.2
Slide 14: Safety: Serious TEAEs
SAFETY: Serious TEAEs Only 3 Serious TEAEs (reported as unrelated) during the study RPC1063 RPC1063 Placebo 0.5 mg 1 mg (N=88) (N=87) (N=83) Preferred Term n (%) n (%) n (%) Total number of Serious TEAEs 0 3 0 Numberof Subjects with 1 Serious TEAE 0 3 (3.4) 0 Opticneuritis* 0 1 (1.1) 0 Somatoform au
Slide 15: Safety: Non-Serious TEAEs
SAFETY: Non-Serious TEAEs No notable cardiac, pulmonary, ophthalmologic, infectious or malignancy TEAEs were observed 3 TEAEs of elevated liver enzymes ( 3x ULN) without clinical signs/symptoms were observed Placebo RPC1063 0.5 mg RPC1063 1 mg Parameter (N=87) (N=85) (N=83) Alanine Aminotransferase
Slide 16: Cardiac Safety Profile of RPC1063
Cardiac Safety Profile of RPC1063 Overall Incidence of Cardiac TEAEs SYSTEM ORGAN CLASS Placebo RPC1063 0.5 mg RPC1063 1 mg Preferred Term (N=88) (N=87) (N=83) CARDIAC DISORDERS 2 (2.3%) 2 (2.3%) 1 (1.2%) Angina Pectoris 0 0 1 (1.2%) First Degree AV Block 1 (1.1%) 0 0 Palpitations 1 (1.1%) 2 (2.3%)
Slide 17: Conclusions
Conclusions Both doses of RPC1063 demonstrated large, significant and consistent reductions of all MRI measures of MS disease activity The overall tolerability and safety profile of RPC1063, including cardiac and hepatic safety results, suggests a favorable risk-benefit profile in the treatment of R